Tranexamic acid and trauma: Current status and knowledge gaps with recommended research priorities

Shock

Volumn 39, Issue 2, 2013, Pages 121-126

  Pusateri, Anthony E ^a   Weiskopf, Richard B ^b   Bebarta, Vikhyat ^c   Butler, Frank ^d   Cestero, Ramon F ^e   Chaudry, Irshad H ^f   Deal, Virgil ^g   Dorlac, Warren C ^h   Gerhardt, Robert T ⁱ   Given, Michael B ^j   Hansen, Dan R ^d   Hoots, W Keith ^k   Klein, Harvey G ^l   MacDonald, Victor W ^m   Mattox, Kenneth L ⁿ   Michael, Rodney A ^m   Mogford, Jon ^o   Montcalm Smith, Elizabeth A ^p   Niemeyer, Debra M ^d   Prusaczyk, W Keith ^q   Rappold, Joseph F ^r   Rassmussen, Todd ⁱ   Rentas, Francisco ^s   Ross, James ^e   Thompson, Christopher ^t   Tucker, Leo D ^u   more..

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Lackland Air Force Base ^*  (United States)

^d Defense Health Board   (United States)

^e Naval Medical Research Unit   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g MacDill Air Force Base   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^j OFFICE OF NAVAL RESEARCH   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m US Army Medical Materiel Development Activity   (United States)

ⁿ BAYLOR COLLEGE OF MEDICINE   (United States)

^o DEFENSE ADVANCED RESEARCH PROJECTS AGENCY   (United States)

^p NAVAL MEDICAL RESEARCH CENTER   (United States)

^q Naval Medical Research and Development Center   (United States)

^r NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^s US Armed Services Blood Program Office   (United States)

^t Naval Undersea Medical Institute   (United States)

^u US Army Medical Command   (United States)

more..

Author keywords

efficacy; research requirements; safety; Tranexamic acid; trauma

Indexed keywords

AMINOCAPROIC ACID; APROTININ; TRANEXAMIC ACID;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; AFGHANISTAN; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG USE; HUMAN; INJURY; ISCHEMIA; KIDNEY DISEASE; LUNG EMBOLISM; MENORRHAGIA; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SURVIVAL; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WAR;

ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH; RISK FACTORS; SEIZURES; THROMBOSIS; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 84872973390     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318280409a     Document Type: Review

References (36)

1. Martin K, Wiesner G, Breuer T, Lange R, Tassani P: The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 107:1783-1790, 2008.
2. Henry D, Carless P, Fergusson D, Laupacis A: The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 180:183-193, 2009.
3. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W: Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 123:687-696, 2009.
4. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C: Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 14:R148, 2010.
5. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, Tassani P, Wiesner G: Seizures after open heart surgery: comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 25: 20-25, 2011.
6. Shakur H, Roberts R, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, et al.: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376:23-32, 2010.
7. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ: Military Application of Tranexamic Acid in Trauma Emergency Resuscitation Study (MATTERS). Arch Surg 147:113-119, 2012.
8. Levi M: Should anifibrinolytics be given in all patients with trauma? Curr Opin Anesthesiol 25:385-388, 2012.
9. Clinical Practice Guideline for Damage Control Resuscitation. Available at: http://www.usaisr.amedd.army.mil/assets/cpgs/Damage-Control-Resuscitation- 17-Jul-12.pdf. Accessed September 24, 2012.
10. Defense Health Board Memorandum. Recommendations Regarding the Addition of Tranexamic Acid to the Tactical Combat Casualty Care Guidelines. September 23, 2011.
11. Committee on Tactical Combat Casualty Care. Military Prehospital Life Support Course 2012, Tactical Combat Casualty Care Guidelines. http://www.health.mil/Education-And-Training/TCCC.aspx. Accessed September 24, 2012.
12. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, et al.: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 377:1096-1101, 1101e1-1101e2, 2011.
13. Weiskopf RB: Assessment of hemostasis through the retrospectroscope. J Thromb Haemost 4:2074-2078, 2006.
14. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, et al.: A comparison of apro-tinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358: 2319-2331, 2008.
15. Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsner MG: Four years of an aggressive prophylaxis and screening protocol for venous thromboem-bolism in a large trauma population. J Trauma 65:300-308, 2008.
16. Ekeh AP, Dominguez KM, Markert RJ, McCarthy MC: Incidence and risk factors for deep venous thrombosis after moderate and severe brain injury. J Trauma 68:912-915, 2010.
17. Furtmuller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H: Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 301:168-173, 2002.
18. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M: High-dose tra-nexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 110:350-353, 2010.
19. Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, Trenk D: High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg 39:e114-e121, 2011.
20. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F: High-dose tranexamic acid is an independent predictor of early seizure after car-diopulmonary bypass. Ann Thorac Surg 93:148-154, 2012.
21. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, Jacobsohn E: Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth 59:6-13, 2012.
22. Koster A, Börgermann J, Zittermann A, Lueth JU, Gillis-Januszewski T, Schirmer U: Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome [published online ahead of print]. Br J Anaesth 110:34-40, 2013.
23. Clinical Practice Guideline for Severe Head trauma. Available at: http://www.usaisr.amedd.army.mil/assets/cpgs/Mgmt-of-Patients-with-%20Severe- Head-Trauma-7-Mar-12.pdf.
24. Perel P, Salman RA, Kawahara T, Morris Z, Prieto-Merino D, Roberts I, Sandercock P, Shakur H, Wardlaw J: CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injuryVa nested randomised, placebo-controlled trial. Health Technol Assess 16:iii-xii, 1-54, 2012.
25. Ide M, Bolliger D, Taketomi T, Tanaka K: Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery [published online ahead of print December 29, 2009]. J Anesth 24(1):96-106, 2010.
26. Brummell-Ziedens K, Orfeo T, Jenny NS, Everse SJ, Mann KG: Blood coagulation and fibrinolysis. In Greer JP, et al., eds. Wintrobes Clinical Hema-tology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:676.
27. Jiménez JJ, Iribarren JL, Brouard M, Hernández D, Palmero S, Jiménez A, Lorente L, Machado P, Borreguero JM, Raya JM, et al.: Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg 6: 138, 2011.
28. Reichel CA, Lerchenberger M, Uhl B, Rehberg M, Berberich N, Zahler S, Waymann MP, Krombach F. Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature. PLoS ONE 6(2):e17229, 2011.
29. Chang M, Kistler EB, Schmid-Schönbein GW: Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall. Shock 37:297-305, 2012.
30. Levy J: Antifibrinolytic therapy: new data and new concepts. Vol 376. July 3, 2010. www.thelancet.com. Accesssed September 24, 2012.
31. Cap AP, Baer DG, Orman JA, Aden J, Ryan K, Blackbourne LH: Tranex-amic acid for trauma patients: a critical review of the literature. J Trauma 71(Suppl 1):S9-S14, 2011.
32. Burk AM, Martin M, Flierl MA, Rittirsch D, Helm M, Lampl L, Bruckner U, Stahl GL, Blom AM, Perl M, et al.: Early complementopathy after multiple injuries in humans. Shock 37:348-354, 2012.
33. Dalle Lucca JJ, Li Y, Simovic M, Pusateri AE, Falabella M, Dubick MA, Tsokos GC: Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage. Shock 38:82-91, 2012.
34. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J: Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anes-thesiology 97:390-399, 2002.
35. Gong H, Wang W, Kwon TH, Jonassen T, Frøkiaer J, Nielsen S: Reduced renal expression of AQP2, p-AQP2 and AQP3 in haemorrhagic shock-induced acute renal failure. Nephrol Dial Transplant. 18(12):2551-2559, 2003.
36. Arkaravichien W, Tamungklang J, Arkaravichien T: Cefazolin-induced seizures in hemodialysis patients. J Med Assoc Thai 89:1981-1983, 2006.